1. Home
  2. SCYX vs LVO Comparison

SCYX vs LVO Comparison

Compare SCYX & LVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.05

Market Cap

44.4M

Sector

Health Care

ML Signal

HOLD

Logo LiveOne Inc.

LVO

LiveOne Inc.

HOLD

Current Price

$2.69

Market Cap

45.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
LVO
Founded
1999
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
45.5M
IPO Year
2014
2010

Fundamental Metrics

Financial Performance
Metric
SCYX
LVO
Price
$5.05
$2.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
★ $36.33
$9.75
AVG Volume (30 Days)
★ 259.2K
112.7K
Earning Date
11-04-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
★ 78.57
EPS
N/A
★ N/A
Revenue
$257,000.00
★ $77,144,000.00
Revenue This Year
N/A
$6.07
Revenue Next Year
$906.41
$27.12
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.57
$2.24
52 Week High
$6.09
$7.19

Technical Indicators

Market Signals
Indicator
SCYX
LVO
Relative Strength Index (RSI) 54.63 37.30
Support Level $4.65 N/A
Resistance Level $5.44 $5.83
Average True Range (ATR) 0.43 0.31
MACD 0.07 -0.01
Stochastic Oscillator 68.31 26.71

Price Performance

Historical Comparison
SCYX
LVO

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About LVO LiveOne Inc.

LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world-wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. Its operations are based in the United States. It generate revenue through the sale of paid user services and advertising from its music offerings, from the licensing, advertising.

Share on Social Networks: